Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.
Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.
In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.
The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.